In recent years we have seen significant regulatory changes in Canada that may affect market access of new drugs and biologics. As we look ahead to 2021, the legal experts at Smart & Biggar report on the recent developments to help innovative life sciences companies navigate the Canadian patent and regulatory landscape.
Smart & Biggar partners Daphne Lainson, Nancy Pei and David Schwartz recorded this timely update on patented medicines in Canada on Thursday, September 10th, including:
Patented medicines pricing reform
- Status of legal challenges to the amended Patented Medicines Regulations
- Coming into force of the new pricing regime of the Patented Medicine Prices Review Board (PMPRB)
- Implications of new law for grandfathered products, line extensions, “gap” drugs and new patented drugs
Patent term extension
- Recent jurisprudence concerning Certificates of Supplementary Protection
- Update on Patent Term Adjustment
Patent law changes
- Patent and patent application maintenance: new risks, greater certainty
- New options for maintaining pendency
- COVID-19 “compulsory licensing”
Events & Webinars
-
- [Webinar Series] Canadian Trademarks: Protection Strategies for Global Brands
Protection Strategies for Global Brands
A timely series of webinars to provide in-house counsel and global IP lawyers with a complete understanding of the unique aspects of Canadian brand protection. Read More -
- 01:00 PM [Webinar Replay] Canadian Trademark Law 2023: Year in Review
Smart & Biggar's trademark team provides a roundup of Canadian IP law by highlighting some of the most important new laws, cases, and practice directions from 2023. Read More -
- [Webinar Series] Canadian Trademarks 2023
A timely series of webinars to provide in-house counsel and global IP lawyers with a complete understanding of the unique aspects of Canadian brand protection. Read More